3 years ago

Choline kinase inhibition and docking studies of a series of 6-(benzylthio)-9 H -purin-9-yl-pyridinium derivatives

Pablo Ríos-Marco, Ana Conejo-García, Antonio Espinosa, Ramon Hurtado-Guerrero, María Paz Carrasco-Jiménez, Antonio Entrena, Belén Rubio-Ruiz, Carmen Marco

Abstract

Human choline kinase is a well validated target for the treatment of cancer. In the last two decades, many choline kinase inhibitors have been developed and one of them is currently under evaluation in clinical trials. In this paper a series of 6-(benzylthio)-9H-purin-9-yl-pyridinium derivatives were evaluated as choline kinase inhibitors, and their effects on cell proliferation were also investigated in the human hepatoma HepG2 cell line. The most potent inhibitor against purified choline kinase-α1 presents an IC50 value of 0.4 μM. The biological data and the docking studies described here, support that the 4-(dimethylamino)pyridinium cationic head and a small linker (benzene or biphenyl) are the essential structural parameters for choline kinase inhibition of the tested compounds.

Publisher URL: https://link.springer.com/article/10.1007/s00044-017-1979-6

DOI: 10.1007/s00044-017-1979-6

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.